Resveratrol VESIsorb (Vineatrol)

[Jacob]

I've contacted some companies that carry some of Source One's other products, but I think it'd be a good idea to try to get Swanson's to carry it. Not gonna hold my breath on any of them carrying it anytime soon..but pleeeeeeeeease..if you're interested(and even if you're not)..just put Resveratrol VESIsorb (Vineatrol) in the form. Ask other places if you want too.


http://www.swansonvitamins.com/product. ... estsellers

http://www.source-1-global.com/products/vesi.html

The tocotrienols would be good too

[kamisama]

just did that. looks good but i wonder how much would it cost.

[Jacob]

Thanks

Yeah..it'll most likely be expensive..like their COq10 is(available via Douglas Labs..places that sell their products I mean..such as http://www.naturalhealthyconcepts.com/c ... tment.html). But everyone keeps complaining and worrying about bioavailability etc..so lipo/nano-some seems to be the way to go at the moment.

But that's another reason why I'm suggesting Swanson's. I would think they would be cheaper under their own label than something from Douglas Labs.

[hapyman]

Just sent one too

[Jacob]

Thanks hapyman

In case anyone is wondering why Resveratrol..or needs a reminder...

http://www.hairloss-research.org/Update ... 11-07.html

There are plenty of Curcumin products out there..the one I would use if I could get a hold of this Resveratrol too..is Swanson's phytosome one. Otherwise I may try that Liposome Resv/Curcumin/COq10 etc combo.

[Jacob]

I'm awaiting confirmation..but may have found a source for this. If it's the right stuff..it's $45.99 for 60. Cheaper than the COq10 at least No link..they say they can get it...will be added to their website eventually.

[Jacob]

And it's not the VESIsorb after all. Does look good though:
https://www.longnaturalhealth.com/products.asp?P=274

A recent clinical study was conducted on Red Wine NP+ microspheres containing red wine polyphenols and confirmed that this patented product has the ability to stimulate the release of NO nitrogen monoxide by the normal human endothelial cells and therefore play a role in the vasodilatation of the blood vessels.

Phytomicrospheres®, a patented delivery system designed to capture the full spectrum of the polyphenolic substances (antioxidants) of Red Wine, allows an optimized release of this extract for maximum bioavailability.

[Jacob]

Flavoprimum ® PPVR (red wine polyphenols) effects on nitric oxide (NO)

Flavoprimum® (patent no. 2 794 346) is made of 350 mg microspheres containing red wine polyphenols that provide antioxidants and helps nitric oxide to be liberated from cells. Phytomicrospheres technology is a new galenic process from Laboratories Michel Iderne which captures the full spectrum of natural substances found in liquids (tinctures, fluid extracts) and simply transfers them into a dry, stable and completely natural form.



Advantages of microspheres:

+ perfect dry extract from a fluid extract of a plant (1/1),
+ excellent yield : 1 kg fluid extract = 1 kg phytomicrospheres,
+ 100% natural, only one single recipient = microcrystalline cellulose,
+ 200 mg of microspheres = 80 drops of a mother tincture,
+ one glass of red wine in one alcohol free gel cap,
+ no sugar,
+ no alcohol,
+ no color,
+ no additives,
+ preservative free,
+ long time stability,
+ better release of active principles :
* twice as much as with a normal plant powder,
+ fast and complete release of active principles as soon as absorbed (99% active after 30 first minutes),
+ improves absorption and distribution of active principles,
+ wider and faster bioavailability.



Flavoprimum® polyphenols promotes the release of nitric oxide (NO) into the extracellular space by normal human endothelial cells (HUVEC), bringing about the relaxation of smooth muscle cells and thus the dilatation of blood vessels.

An analytical evaluation (Report N° 072901) has been done by Agrobio-Nutrinov laboratory to evaluate the release of the nitric monoxyde NO by the endothelial cells from red wine polyphenols contained in Flavoprimum®. This experiment was conducted in an ex vivo study on human endothelial cells in culture.

The following data were obtained.

A low concentration of red wine polyphenols (PPVR) seems to stimulate cellular proliferation and/or growth (increase up to 30% of mitochondrial activity: MTT test for concentration 50 μg/ml; increase up to 43% of cellular viability: neutral red test [test au rouge neutre], p<0.01 for concentration 12.5 μg/ml).

At high doses, 400 μg/ml, the PPVR show a slight toxicity: the cell morphology changes, vesicles seem to form on the surface of the cells and their quantity increases, depending on the concentration, to the point where the cells become round and lose their cytoplasm (an over secretion of NO inducing a strong oxidant stress and lysing the contents of the cell).

Red wine polyphenols released by Flavoprimum® are absorbed by the intestinal cells and may thus have the capacity to stimulate the release of NO by the endothelial cells and could thus play a role in the vasodilatation of blood vessels.

Flavoprimum®takes the form of capsules containing microspheres which release nitric oxide (NO) by the endothelial cells. Indeed, NO is a cellular second messenger inducing the relaxation of smooth muscle cells and thus favouring the dilatation of the blood vessels.

One capsule contains 350 mg of microspheres containing polyphenols.

In vivo, the release of the active agents during digestion is 100%, with 100 % intestinal absorption, a one-capsule dose will enable the cells to be in contact with 12.5 μg/ml total polyphenols.

For practical reasons, the experiments on cells were done using the polyphenol solution that was used to make the microspheres.

During the first stage only the cells treated with the 12.5 μg/ml concentration of Flavoprimum® PPVRs were tested in parallel to untreated control cells and to the positive reference A23187.

The molecule A23187 is a calcic ionophore. It makes holes in the cell membranes allowing the calcium present in the experimental medium to enter the cells and to activate different cell enzymes including NOS (nitric oxide synthesise), an enzyme that releases NO from arginine (biological precursor, contained in the experimental medium).

A23187 is a mobile ion-carrier that forms stable complexes with divalent cations (ions with a charge of +2). A23187 is also known as Calcimycin, Calcium Ionophore, Antibiotic A23187 and Calcium Ionophore A23187. It is produced at fermentation of Streptomyces Chartreusensis.

During the first experiment, the reference A23187 showed an increase of more than 100% compared to the control cells and the Flavoprimum® PPVRs at 12.5 μg/ml, an increase of almost 70%.

During the second experiment, the 6.66 μg/ml and 12.5 μg/ml concentrations of Flavoprimum® PPVR 6 were tested in parallel to untreated control cells and the positive reference A23187.

In this experiment, the reference A23187 showed an increase of over 200% compared to the control cells and the Flavoprimum® PPVRs increases of almost 70% and over 188% for the 6.66 μg/ml and 12.5 μg/ml concentrations respectively.

The positive reference A23187 gives the maximum response and the control cells the minimum response. The response of the Flavoprimum® PPVRs is situated between the two extremes.

The percentage response with the Flavoprimum® PPVRs used at 12.5 μg/ml compared to the positive reference A23187 is virtually the same for the two experiments (approximately 90%). The method can therefore be used to compare the cells treated with the positive reference A23187 and the cells treated with the product to be tested.

It would seem here that the Flavoprimum® PPVRs tested in this study and used at 12.5 μg/ml respond at 90% of the maximum response. At the 6.66 μg/ml concentration, the cells synthesise and secrete 50% of the maximum. It would also seem that there is a dose-dependent effect.



Conclusions

- The 6.66 μg/ml and 12.5 μg/ml doses tested correspond to the administration of one or 2 capsules per day if we consider that all that is released are absorbed by the intestinal cells.

- The two experiments showed that for the 12.5 μg/ml concentration of Flavoprimum® PPVRs the cells synthesised and secreted 90% of the maximum possible nitric oxide (100% corresponding to the positive reference A23187) in the experimental conditions used here. At the 6.66 μg/ml concentration, the cells synthesised and secreted 50% of the maximum. Flavoprimum® microspheres containing red wine polyphenols would therefore have the ability to stimulate the release of nitric oxide NO by the endothelial cells and might therefore play a role in the vasodilatation of the blood vessels.

Thus, red wine global extracts (Flavoprimum®) including its whole components (polyphenols, phenolic acids, etc.) have been shown to exert activity on several physiological functions, which explains why they can be considered substances of natural extraction with the following properties:

* stimulant of cellular growth,
* smooth muscle relaxant,
* vasodilator,
* reactional blood flow increasing agent,
* vascular eutrophic,
* platelet aggregation reductor,
* microbicidal,
* non-adrenergic and non-cholinergic neurotransmitter,
* gastrointestinal musculotropic antispasmodic,
* role in long-term memory,
* essential regulator of cellular apoptosis, with ambivalent action that can be either apoptotic or anti-apoptotic,
* stimulant of erection by vasodilatation.



In modifying the tone of the blood vessels by the release of NO, Flavoprimum® is a vasodilator endowed with a eutrophic and platelet-antiaggregant activity that allows a better regulation of vascular dynamics, and therefore of tissular oxygenation, and as a result a better metabolic functioning of the organism. Added to this eutrophic activity is an activity of regulation of cellular apoptosis, and a microbicidal action, making Flavoprimum® a major therapeutic agent for a vascular terrain that is either partially or totally degraded, whether or not the hypo-oxygenation characteristic of this type of terrain is localised to a particular organ, and whether or not the consequences of this pathological mechanism have affected the whole organism. It may also have an effect on long-term memory through its action on the blood vessels and on certain neurotransmitters.

Given the diverse physiological activities of NO, and of those linked to the various constituents of Flavoprimum®, one can expect a wide range of physiological and clinical effects from its prescription, concerning for example energy maintenance in the individual, prevention of degenerative phenomena – both vascular and musculoskeletal – and management of stress in relation to certain hormonal axes that tend to induce specific pathologies.


Flavoprimum® case studies

The following cases concern 3 patients with chronic conditions involving either cardiovascular or neurological manifestations. These patients had been treated for many years by conventional treatments and by plant-based therapeutic preparations, and adding Flavoprimum® red wine extract to their treatment, at the dose of 6 capsules a day, led in a few weeks to an improvement in certain of their clinical signs.

No tests to determine oxidative stress were carried out. The results presented here are based solely on an evaluation of the development of their clinical state. They are given purely for information, and as a basis for reflection, which could prompt others to set up trials using a more significant number of subjects.

The interest of these case studies is such that they deserve to serve as a basis for more extensive studies – studies using standardised protocols to try to understand whether there exists a relationship between the change in the level of patients’ oxidative stress and the clinical improvement observed.

However, the scientific data that we have at present concerning the physiological effects of red wine extracts allow us to surmise that the clinical progress observed in these three patients may be related to an improvement in their oxidative status, in their microcirculation and in their overall metabolic state.


Multiple sclerosis

Mme Marcelle P. was 35 when she consulted us for the first time in 2001. She presented with a multiple sclerosis that had first appeared when she was about 20, manifesting as a tendency to become fatigued on walking. Successive flare-ups of the illness had increasingly limited her autonomy. The conventional treatments based on cortisone and muscle relaxants had not managed to reduce the frequency of her relapses, which involved problems with vision and swallowing, pins and needles around the mouth, abnormal sensations to the touch, and fits of dizziness that made her afraid that she would have to resort to the short-term use of a wheelchair. Her state of mind was deteriorating from day to day.

On clinical examination there existed a reflex hyperspasmodicity and a pyramidal-type stiffness, with multiple neurological signs reflecting the diffusion of the neurological effects, which had spread throughout the cranial nerves. The circulatory imbalance was obvious, with frozen, purplish and edematous legs and feet.

The overall interpretation of all the problems presented by Mme P. led us to the conclusion that her MS involved the participation not only of the immune system but also of several hormonal and autonomic nervous system factors that brought into play the thyroid gland, the pancreas, and certain pituitary and ovarian elements, as well as her alpha-sympathetic system. Terrain treatments, essentially comprising medicinal plants, oligo-elements and vitamins chosen for their ability to correct the physiological problems that had been noted, have been regularly prescribed over the last seven years.

The introduction of Flavoprimum® in 2006 as a complement to her main treatment, at the dose of 6 capsules a day, has permitted a modification of the state of the patient’s circulatory and peripheral vasomotor system. For while the appearance of the lower limbs had remained unchanged since the beginning of the illness, we now noted a progressive increase in the warmth of the feet and legs, as well as a net reduction in the local edema, and a return of color to the tissues, with a progressive disappearance of the purplish hue. Subjectively, the patient said that she felt much more comfortable, and had lost the disagreeable sensation of having frozen feet, which she had always felt.

A better management of her peripheral circulatory equilibrium had no doubt played a major role in the improvement observed, and could be explained in part by the physiological effects that red wine polyphenols and Nitric oxide NO induced production at tissular level are likely to produce, such as: vasodilatation, eutrophic and platelet anti-aggregant activity, and improvements in circulatory dynamics and tissular oxygenation.

The combination of these different effects could thus lead to a better metabolic functioning of the organism as a whole.


Diabetes with polyneuritis

M. Christian M. was 63 when, in 1998, he was diagnosed with diabetes following the sudden onset of an intense polyneuritis. His fasting blood sugar level was 3.56 g/l, rising to 4.07 g/l after meals. The nerve pains in his lower limbs were so violent that they prevented the patient from sleeping, leading to a profound deterioration in his general condition. It was proposed that he be immediately hospitalised and given insulin therapy (3 injections a day).

The patient would only consent to oral therapy, and so a very precise diet and a hypoglycemic sulfamide was prescribed, together with medicinal plants to support and drain the liver, pancreas and kidneys, with the aim of correcting the tone of the arteries and veins and modifying the reactivity of the sympathetic system. Within two months the blood sugar level had normalised, and he continued to follow the treatment. But the pains linked to his polyneuritis persisted, and, being worse at night, had a permanent negative effect on his sleep, to the point that the diabetes specialist was obliged to prescribe morphinomimetic drugs for a period of several years.

As soon as the prescription of these sedatives was reduced, the pains immediately returned, each time more and more intensely. In 2006 Flavoprimum® was added to his main treatment, at a dose of 6 capsules per day. In a few weeks the pains eased, finally disappearing after three months. The condition was definitively cured, and this allowed the patient to stop taking for good the morphinomimetics, after several years of continuous usage.

This example demonstrates that, even in difficult cases where severe metabolic anomalies generate long-term neuropathic problems, the potential for controlling oxidoreduction offered by the red wine polyphenols contained in Flavoprimum® can permit the reduction and disappearance of painful and debilitating symptoms, probably through their positive effect on the dysregulation of oxygenation mechanisms in the vessels and the nervous system.


Atherosclerosis

M. Nicolas G., aged 55, was hospitalised in February 1985 in the cardiac unit of a Paris hospital for a cardiovascular check-up. For several months he had been feeling more and more discomfort when walking quickly or immediately after meals. Since the crises of angina were getting worse, he was given a full check-up, which revealed the presence of advanced atheroma in three of his four coronary arteries, with a narrowing of several collateral branches of the arteries nourishing the heart. The extent of the lesions led his cardiologists to propose ‘a bypass of at least the right coronary artery and the anterior interventricular artery and perhaps the lateral network’.

Since he categorically refused the intervention that was proposed to him, he was placed on calcium channel blockers and beta-blockers together with a terrain treatment comprising various medicinal plants. Thanks to these treatments, he was able to lead an almost normal life for more than 20 years, but he still experienced shortness of breath after meals and on effort that had always been there since the discovery of the illness, in spite of the various modifications that had been made to his treatments.

The prescription of Flavoprimum® in 2006, at a dose of 6 capsules a day, was to bring about, in less than two months, such an improvement that all the symptoms reflecting a chronic under-oxygenation of the myocardium had disappeared. At the present time, two years later, none of his problems has reappeared, and this patient can walk normally, and for an extended period of time, without experiencing the slightest symptom.

One can legitimately hypothesise that Flavoprimum® led to a more efficient use of oxygen by the heart.



As a conclusion

Cardiovascular and degenerative diseases are widely spread all over the world and constitute a true public health problem. The biological mechanisms which are implicated in such diseases are for a large part linked to a bad management of normal physiological oxidoreduction activities by the body. Red wine polyphenols which are contained in Flavoprimum®, aside its other contents, appears as a good non toxic and natural response to these problems, allowing the organism to improve its ability to recover a better global balance. By the fact of global effects of all the red wine components that it contains, Flavoprimum could play a major role at various levels of the organism: to protect vascular walls from oxidation, to fight inflammation, to decrease platelets aggregation and thrombus formation risk, to oppose to oxidative modification of lipids , to better face oxidative stress, to help the body to better manage cancer risks and ageing problems.

[Jacob]

Here's the product https://www.longnaturalhealth.com/products.asp?P=274

Will be trying this out for a bit. I've given up on the VESIsorb one..when and if it comes out I'll try it then

[Jacob]

Study reveals absorption power of nanotech delivery system
By staff reporter, 15-Oct-2009

Related topics: Phytochemicals, plant extracts, Cardiovascular health

SourceOne claims a new human study on the nanotech delivery system Vesisorb illustrates its power to improve the absorption and bioavailability of PMFs.

Polymethoxylated flavones (PMFs) are citrus ingredients used for heart health applications. Where Vesisorb can help is in boosting the rate at which they are absorbed into the human body.

Citrus CMFs are notoriously poorly absorbed in the body, according to Dr Andreas Supersaxo, R&D director at Swiss firm Vesifact, which developed the delivery system.

Bioavailability study

To put it to the test a bioavailability study was conducted (single oral dose, double-blind, crossover design) to compare standard PMF powder with SourceOne’s PMF-Source and the Vesisorb delivery system.

What the test results indicate, according to SourceOne, which holds the exclusive global licensing rights for the Vesisorb technology, is that PMF absorption of the Vesisorb formulation was significantly improved and faster compared to standard PMF. Peak plasma levels (Cmax) of Nobiletin, Tangeretin and their metabolites were increased by up to 800 per cent.

Supersaxo said the results demonstrate the “clear potential for greater efficacy and improved health and wellness for formulations containing Citrus PMF, HO-PMFs, Citrus Limonoids, and Eriocitrin/Eriodictyol.”

Recent studies

Research on the effect of Vesisorb on PMF-Source follows on from studies regarding its impact on the absorption of Omega-3 and CoQ10.

SourceOne highlighted two pharmacokinetic studies on Omega-3 and CoQ10 that both compared formulations using the Vesifact delivery system with ones without. They recorded increases in bioavailability of 485 percent in the case of CoQ10 and 487 percent for Omega-3.

“These results, including the newest study, highlight the many advantages that this delivery system represents,” said Vesifact CEO Marc Weder. “We have been able to broaden the applications for certain bioactive ingredients like PMFs, CoQ10, and omega 3 into functional ingredients, beverages, and cosmetic products.”

http://www.nutraingredients-usa.com/Res ... er%2BDaily

[Jacob]

Looks like a Vesisorb Resv product will be out soon: http://itakestatins.com/products.html